This point can be readily appreciated by analyzing AR genomic amplifications (AMP) in 2,045 PCa cases in the MSK-IMPACT 2021 dataset consisting of 1,062 primary tumors, 578 metastatic hormone-sensitive PCa (mHSPC) and 405 mCRPC patients [37]: AR AMP was virtually non-existent in primary PCa and very low (4%) in mHSPC but was detected in 47% of mCRPC (Figure 2A), indicating that AR AMP is strictly treatment-induced! The gene discussed is AR; the disease is posterior cortical atrophy.